Turks had a Great Performance in the Biological Molecule Project
Developed by Ege University and TRPHARM for the treatment of Behçet Syndrome and Familial Mediterranean Fever, RHP-104 biolog...
Turks had a Great Performance in the Biological Molecule Project
Phase 1 clinical studies for the biological molecule called RPH-104, developed by Ege University Research and Application Center of Drug Development and Pharmacokinetics (ARGEFAR) and TRPHARM company for the treatment of Behçet Syndrome and Familial Mediterranean Fever.
Rector Yılmaz noted that the biggest problems in the world would be about health, water, and environment in the future, and that they conducted studies in this context at ARGEFAR Phase 1 Clinic.
Indicating that many studies on drug development have been conducted at Ege University, Candeğer Yılmaz also explained that a candidate molecule had been developed to be used for the treatments of Familial Mediterranean Fever and Behçet Syndrome, which are prevalent diseases in the region, and that the first Phase 1 studies of that molecule in Turkey would be conducted at ARGEFAR.
Stating that the academical studies on drug development have been conducted and the process for the authorization of the drug will continue, Prof. Dr. Yılmaz said that the drug might be launched in 5-8 years thanks to the investor company TRPHARM.
"Personal treatment will be administered"
Assistant Manager at ARGEFAR, Prof. Dr. Sibel Göksel explained that drug development was a long process and that drugs were tested on animals first, and then Phase 1 studies on humans would start once the drugs were found safe and effective.
Indicating that the biological agent, developed within the context of the studies, aims a specific target and dominates its effect, Göksel noted: "We will conduct the first Phase 1 study with that agent. All drugs are examined in terms of their safety an efficacy on healthy individuals before they are launched. This will be the first study with this agent."
Cardiology specialist Assoc. Prof. Dr. Uğur Önsel stated that the average lifespan in Turkey had increased 6 years in the last 20 years thanks to innovative treatments, and "The drug will act against the existence mechanism of the disease. It is aimed to be applied with the subcutaneous injection method. Personal treatment will be administered," he added.
Tuygan Göker, the President of TRPHARM, explained that Turkey would no longer be a country only following the drug studies in foreign countries and trying to attend multinational clinical program, and he added that TRPHARM would support the production of biotechnical drugs in Turkey.
Rector Yılmaz noted that the biggest problems in the world would be about health, water, and environment in the future, and that they conducted studies in this context at ARGEFAR Phase 1 Clinic.
Indicating that many studies on drug development have been conducted at Ege University, Candeğer Yılmaz also explained that a candidate molecule had been developed to be used for the treatments of Familial Mediterranean Fever and Behçet Syndrome, which are prevalent diseases in the region, and that the first Phase 1 studies of that molecule in Turkey would be conducted at ARGEFAR.
Stating that the academical studies on drug development have been conducted and the process for the authorization of the drug will continue, Prof. Dr. Yılmaz said that the drug might be launched in 5-8 years thanks to the investor company TRPHARM.
"Personal treatment will be administered"
Assistant Manager at ARGEFAR, Prof. Dr. Sibel Göksel explained that drug development was a long process and that drugs were tested on animals first, and then Phase 1 studies on humans would start once the drugs were found safe and effective.
Indicating that the biological agent, developed within the context of the studies, aims a specific target and dominates its effect, Göksel noted: "We will conduct the first Phase 1 study with that agent. All drugs are examined in terms of their safety an efficacy on healthy individuals before they are launched. This will be the first study with this agent."
Cardiology specialist Assoc. Prof. Dr. Uğur Önsel stated that the average lifespan in Turkey had increased 6 years in the last 20 years thanks to innovative treatments, and "The drug will act against the existence mechanism of the disease. It is aimed to be applied with the subcutaneous injection method. Personal treatment will be administered," he added.
Tuygan Göker, the President of TRPHARM, explained that Turkey would no longer be a country only following the drug studies in foreign countries and trying to attend multinational clinical program, and he added that TRPHARM would support the production of biotechnical drugs in Turkey.